JPWO2021209732A5 - - Google Patents

Claims (16)

A method for predicting stroke as a result of large vessel occlusion (LVO), the amount of at least two biomarkers in a sample obtained from an individual having, identified or suspected of having had a stroke. wherein the biomarkers are D-dimer and glial fibrillary acidic protein (GFAP). A method for identifying individuals who have suffered a stroke as a result of LVO from a group of individuals who have or are identified or suspected to have had a stroke, the method comprising at least two species in a sample taken from each individual. determining the amount of a biomarker, wherein the biomarker is D-dimer and glial fibrillary acidic protein (GFAP). determining the amount of up to two additional biomarkers , wherein the up to two additional biomarkers are osteopontin (OPN) and/or osteoprotegerin (OPG). The method described in Section 1 or 2. The amount of each biomarker in said sample taken from said individual who has or is identified or suspected to have had a stroke as a control, positive standard, one or more positive standards or negative standards. comparing the amount of the same biomarker in one or more of the
Optionally, said individual has a measured amount of one or more of said biomarkers that is different from the amount of the same biomarker in a control or negative standard, or an amount of the same biomarker in a positive standard. 4. The method according to any one of claims 1 to 3 , wherein the patient has or is judged to have had a stroke as a result of LVO if the patient has a stroke as a result of LVO . 4. An increase in the amount of D-dimer, OPN and/or OPG when compared to a healthy or non-LVO control or negative standard indicates that the individual has suffered a stroke as a result of LVO . The method described in. 6. The method of claim 4 or 5, wherein a decrease in the amount of GFAP when compared to a healthy or non-LVO control or negative baseline indicates that the individual has suffered a stroke as a result of LVO. 7. The method of any one of claims 1 to 6 , wherein the sample from the individual is one or more of blood, plasma, cerebrospinal fluid or saliva. From claim 1, further comprising the step of determining a stroke severity score from said individual, preferably said stroke severity score being selected from NIHSS, FAST, FAST-ED, RACE, C-STAT and EMSA. 7. The method described in any one of 7 . combining the amount of one or more biomarkers measured in said sample from an individual identified or suspected of having or having had stroke with a stroke severity score obtained from said individual; 9. The method according to any one of claims 1 to 8 , comprising the step of determining an LVO stroke score. comparing an LVO stroke score generated from an individual identified or suspected of having or having had a stroke to an LVO stroke score generated from a control or from a positive standard ;
Optionally, said individual has a stroke, or said LVO stroke score generated using said biomarker amount measured in a sample taken from an individual identified or suspected to have had a stroke is positive. is equivalent to the LVO stroke score generated using the amount of biomarkers from a standard of having or having had a stroke as a result of LVO if said LVO stroke score generated using a biomarker amount is different from said LVO stroke score generated using a biomarker amount from a control; 10. The method of claim 9 , wherein: The amount of a biomarker in said sample taken from said individual identified or suspected of having or having had a stroke is determined using an agent that binds to said biomarker, preferably an agent that binds to said biomarker. 11. A method according to any one of claims 1 to 10 , wherein the amount is determined using ELISA or a lateral flow assay. within about 24 hours of the onset of stroke symptoms in said individual , preferably within about 10 hours of the onset of stroke symptoms in said individual, more preferably within 6 hours of the onset of stroke symptoms in said individual. 12. The method according to any one of claims 1 to 11, wherein the method is carried out in a method according to any one of claims 1 to 11 . Use of at least two biomarkers to predict stroke resulting from large vessel occlusion (LVO) in an individual having or suspected of having had a stroke, wherein the biomarkers include D-dimer and glial fibers. Acidic protein (GFAP) is used. Up to two additional biomarkers may be used to predict stroke resulting from LVO in individuals who have or are suspected of having stroke, and up to two additional biomarkers may be used to predict stroke resulting from LVO in individuals who have or are suspected of having stroke; (OPN) and/or osteoprotegerin (OPG). A pharmaceutical composition for predicting stroke as a result of large vessel occlusion (LVO) , comprising D-dimer and GFAP . A kit for carrying out the method according to any one of claims 1 to 12 , for holding a sample from said individual who has or is identified or suspected to have had a stroke. a container; a means for determining the amount of the target biomarker; and instructions for how to carry out the reaction of the sample provided with the means for determining the amount of the target biomarker. A kit comprising one or more of.